



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/88, 15/60, 15/85, 5/10		A1	(11) International Publication Number: WO 99/01547
			(43) International Publication Date: 14 January 1999 (14.01.99)
(21) International Application Number: PCT/US98/13694		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 1 July 1998 (01.07.98)			
(30) Priority Data: 08/886,550 1 July 1997 (01.07.97) US 60/070,904 1 July 1997 (01.07.97) US			
(71) Applicant (for all designated States except US): COR THERAPEUTICS, INC. [US/US]; 256 E. Grand Avenue, South San Francisco, CA 94080 (US).			
(72) Inventor; and			
(75) Inventor/Applicant (for US only): TOMLINSON, James, A. [US/US]; 1540 Balboa Street, Burlingame, CA 94010 (US).			
(74) Agents: ADLER, Reid, G. et al.; Morgan, Lewis & Bockius LLP, 1800 M Street, N.W., Washington, DC 20036-5869 (US).			
		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: CLONING AND CHARACTERIZATION OF A HUMAN ADENYLYL CYCLASE			
(57) Abstract			
A DNA sequence encoding a human adenylyl cyclase is described. The amino acid sequence of the adenylyl cyclase is also described.			
<pre>GGGAGGAGG GAGGAGGAG GGGAGGAGG AGGGAGGAG GGGAGGAGG 50 GGGAGGAGG GAGGAGGAG GGGAGGAGG AGGGAGGAG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG 100 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG 150 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG MetSer TGGTGTAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG 200 AGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG TyrPheSerG LysLeuLeuVal ProLysVal AspGluArgLys TyrAlaLeu GGGAGGAGG AGGAGGAGG AGGAGGAGG AGGAGGAGG AGGAGGAGG 250 GGGAGGAGG AGGAGGAGG AGGAGGAGG AGGAGGAGG AGGAGGAGG pGlyGluArg AsnGlyGlnLys ArgSerSerG ArgArgGly ThrArgAlaG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG 300 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG LysGlyPheCys SerProArg TyrMetSerCys LysLeuArgAsp AlaGluPro GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG 350 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG ProSerProTyr LysProAlaGly TyrProArg CysProArg LysAlaAla GGGAGGAGG AGGAGGAGG AGGAGGAGG AGGAGGAGG AGGAGGAGG 400 GGGAGGAGG AGGAGGAGG AGGAGGAGG AGGAGGAGG AGGAGGAGG AlaPheLeuArg ArgGlyGlyPhe ArgGlyGly LysGlyLeu GlyLeuArg GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG 450 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG LysValAlaLeu LysGlyPheGlu AspGlyGly LysGlyGly LysGlyGly AGGAGGAGG AGGAGGAGG AGGAGGAGG AGGAGGAGG AGGAGGAGG 500 AGGAGGAGG AGGAGGAGG AGGAGGAGG AGGAGGAGG AGGAGGAGG ThrAlaGluVal AlaAlaProAsp AlaValPro ArgSerGlyArg SerSerCysTyr GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG 550 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG ArgArgLeuValGlyValPheGlySerGlySerGlySerGlySerGlySerGly TGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG 600 AGGAGGAGG AGGAGGAGG AGGAGGAGG AGGAGGAGG AGGAGGAGG GlyGlyGly LysGlyGly TyrGlyGly TyrGlyGly LysGlyGly</pre>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Cloning and characterization of a human adenylyl cyclase

Field of the Invention

This invention relates to DNA encoding a human adenylyl cyclase. This invention also relates to the adenylyl cyclase encoded by that DNA. Referred to herein as the human
5 type VI adenylyl cyclase (hAC6) polypeptide, this enzyme can be used as a tool to screen for agonists and antagonists that can either stimulate or inhibit type VI adenylyl cyclase activity. Such compounds have therapeutic utility in treating (1) diseases that are caused by aberrant activity of this enzyme and (2) diseases whose symptoms can be ameliorated by stimulating or inhibiting the activity of type VI adenylyl cyclase.

10 The present invention also relates to the isolated entire human gene encoding the human type VI adenylyl cyclase, methods for the recombinant production of purified human type VI adenylyl cyclase and the proteins made by these methods, antibodies against the whole human type VI adenylyl cyclase or regions thereof, vectors, nucleotide probes, and host cells transformed by genes encoding polypeptides having human type VI
15 adenylyl cyclase activity, along with diagnostic and therapeutic uses for these various reagents.

Background of the Invention

Adenylyl cyclases direct the intracellular synthesis of the primary second messenger, cyclic-3',5'-adenosine monophosphate (cAMP), by converting ATP to cAMP,
20 principally in response to a diverse family of membrane spanning, G-protein coupled receptors, each activated by its own extracellular hormone or protease. Signal transduction for G-protein coupled receptors occurs through a coupled heterotrimeric G protein complex composed of the alpha (G_α), and beta/gamma ($G_{\beta\gamma}$) subunits. Upon receptor stimulation, G_α exchanges GTP for GDP, dissociates from both $G_{\beta\gamma}$ and the
25 receptor, and proceeds to directly regulate various effectors, including adenylyl cyclase. Multiple families of G_α proteins have been identified, two of which are named for their effects on regulating adenylyl cyclase activity ($G_{\alpha s}$ family stimulates all adenylyl cyclases, while $G_{\alpha i}$ family inhibits most but not all of the adenylyl cyclases). Each of these G_α proteins has its own tissue distribution, and subset of coupled receptors, which favors
30 receptor specific regulation of adenylyl cyclase.

Additional studies have suggested other means by which adenylyl cyclase activity may be regulated within tissues. This concept is derived from findings that a number of adenylyl cyclase isoforms exist, each with their own gene locus, distinct set of responses to intracellular signals and unique tissue distribution. To date, nine separate isoforms
5 (Types I-IX) have been characterized, principally from rodents, each with its own regulatory properties and tissue specific distribution.

The structure of adenylyl cyclases has been greatly studied and the putative domains given standard nomenclature. Topographically, the adenylyl cyclase isoforms are similar, having two six-transmembrane spanning regions associated with an
10 intracellular N-terminus, a large cytoplasmic loop (ICD III, more commonly referred to as "C₁") and an intracellular C-terminus (more commonly referred to as "C₂"). The transmembrane region between the N-terminus and the C₁ loop is commonly referred to as "M1". The M1 region has three extracellular domains (ECD I, II and III), two intracellular domains (ICD I and II) and six transmembrane domains (TM I, II, III, IV, V
15 and VI). The region between the C₁ loop and the C-terminus is referred to as "M2". The M2 region has three extracellular domains (ECD IV, V and VI), two intracellular domains (ICD IV and V) and six transmembrane domains (TM VII, VIII, IX, X, XI and XII). The N-terminus is commonly divided into two regions, designated "N₁" and "N₂". The large C₁ cytoplasmic loop is also divided into two regions, a long "C_{1a}" region and a
20 shorter "C_{1b}" region. Lastly, the C-terminus is divided into a long "C_{2a}" region and a shorter "C_{2b}" region. An extensive discussion of these regions can be found in Broach, *et al.*, WO 95/30012, which is incorporated herein by reference. The amino acid sequence of the C_{1a} and C_{2a} regions are conserved among the different isoforms. On the other hand, the N-terminus, C_{1b} and C_{2b} regions show the most diversity among the various
25 isoforms.

Based on sequence and functional similarities, these isoforms fall into six distinct classes of adenylyl cyclases. Type VI is in the same class as type V, showing sequence similarity even in the transmembrane regions where the greatest level of divergence is noted among the isoforms. Type V is predominantly expressed in heart and brain tissue.
30 Type VI has a somewhat broader distribution, but its dominant expression is also in heart and brain tissue. Type VI, like type V, has a relatively longer N-terminus and relatively

shorter C-terminus, lacking the C_{2b} region, than the other isoforms.

Diversity in activities, and differences in distribution and prevalence of adenylyl cyclase isoforms, may contribute to tissue specific regulation of cAMP levels. It is expected that by taking advantage of distinct structural and biochemical differences
5 between different adenylyl cyclases, isoform specific or selective modulators can be discovered. This, in conjunction with knowledge of the proportion and distribution of each isoform in select tissues provides a means by which one can develop either tissue specific, or selective pharmacological agents since it is expected that isoform-specific modulators would have tissue specificity related to the distribution of that isoform.

10 Key to the development of selective pharmacological agents is information pertaining to the tissue specific distribution and prevalence of each isoform. To date most of this information is available for isoform mRNA levels in a handful of non-human mammals, although some select mRNA (e.g. Type V) have been measured for many human tissues. Acquiring information on protein isoform distribution in human tissues is
15 considered an important aspect of pharmaceutical research in this area, since this could either strengthen existing target information or point to different isoforms, when compared with mRNA data.

To date, only three full length human adenylyl cyclase isoforms have been cloned: Type II adenylyl cyclase (Stengel, *et al.*, Hum. Genet. 90:126-130 (1992)), Type VII
20 adenylyl cyclase (Nomura, *et al.*, DNA Research 1:27-35 (1994)) and Type VIII adenylyl cyclase (Defer, *et al.*, FEBS Letters 351:109-113 (1994)).

Type VI has been cloned from mouse NCB-20 cells (Yoshimura, *et al.*, Proc. Natl. Acad. Sci. USA 89:6716-6720 (1992)) and canine heart (Katsushika, *et al.*, Proc. Natl. Acad. Sci. USA 89:8774-8778 (1992) and Ishikawa, U.S. Patent No. 5,334,521).
25 The human isoform has not been cloned until now.

Summary Of The Invention

One aspect of the invention is an isolated and purified human type VI adenylyl cyclase (hAC6) polypeptide comprising the amino acid sequence of Figure 1 (SEQ ID NO:2).

Another aspect of the invention is an isolated and purified nucleic acid encoding for the hAC6 polypeptide.

Yet another aspect of the invention is an isolated and purified nucleic acid comprising the nucleotide sequence of Figure 1 (SEQ ID NO:1) , which encodes a
5 biologically active hAC6 polypeptide, or fragment thereof.

Still another aspect of the invention is an isolated and purified nucleic acid comprising the nucleotide sequence of Figure 1 (SEQ ID NO:1) , which encodes a biologically active soluble hAC6 peptide fragment.

Another aspect of the present invention also relates to the human gene encoding
10 human type VI adenylyl cyclase, which has both diagnostic and therapeutic uses as are described below. Included within this invention are proteins or peptides having substantial homology with proteins or peptides comprising the amino acid sequence of Figure 1 or encoded by a gene having substantial homology with the nucleotide sequence of Figure 1, and which exhibit the same characteristics of human type VI adenylyl
15 cyclase.

Yet another aspect of the invention is a method of producing hAC6 which comprises incorporating a nucleic acid having the nucleotide sequence of Figure 1 (SEQ ID NO:1) into an expression vector, transforming a host cell with the vector and culturing the transformed host cell under conditions which result in expression of the gene.

20 Brief Description Of The Drawings

Figure 1(A-I) is the DNA (SEQ ID NO:1) and deduced amino acid sequence (SEQ ID NO:2) of human type VI adenylyl cyclase. The entire coding sequence, as well as portions of the 5' and 3' untranslated sequences, are shown. The whole sequence was done bidirectionally twice by dideoxy sequencing method using Taq polymerase.

25 Detailed Description Of The Invention

Definitions

Before proceeding further with a description of the specific embodiments of the present invention, a number of terms will be defined:

The terms "substantially pure" and "isolated" are used herein to describe a protein that has been separated from the native contaminants or components that naturally accompany it. Typically, a monomeric protein is substantially pure when at least about 60 to 70% of a sample exhibits a single polypeptide backbone. Minor variants or
5 chemical modifications typically share approximately the same polypeptide sequence. A substantially pure protein will typically comprise over about 85 to 90% of a protein sample, preferably will comprise at least about 95%, and more preferably will be over about 99% pure. Purity is typically measured on a polyacrylamide gel, with homogeneity determined by staining. For certain purposes, high resolution will be desired and HPLC
10 or a similar means for purification utilized. However, for most purposes, a simple chromatography column or polyacrylamide gel will be used to determine purity. Whether soluble or membrane bound, the present invention provides for substantially pure preparations. Various methods for their isolation from biological material may be devised, based in part upon the structural and functional descriptions contained herein. In
15 addition, a protein that is chemically synthesized or synthesized in a cellular system that is different from the cell from which it naturally originates, will be substantially pure. The term is also used to describe proteins and nucleic acids that have been synthesized in heterologous mammalian cells, bacterial cells such as *E. coli* and other prokaryotes.

As used herein, the terms "hybridization" (hybridizing) and "specificity" (specific
20 for) in the context of nucleotide sequences are used interchangeably. The ability of two nucleotide sequences to hybridize to each other is based upon a degree of complementarity of the two nucleotide sequences, which in turn is based on the fraction of matched complementary nucleotide pairs. The more nucleotides in a given sequence that are complementary to another sequence, the greater the degree of hybridization of
25 one to the other. The degree of hybridization also depends on the conditions of stringency which include temperature, solvent ratios, salt concentrations, and the like. In particular, "selective hybridization" pertains to conditions in which the degree of hybridization of a polynucleotide of the invention to its target would require complete or nearly complete complementarity. The complementarity must be sufficiently high so as to
30 assure that the polynucleotide of the invention will bind specifically to the target relative to binding other nucleic acids present in the hybridization medium. With selective

hybridization, complementarity will be 90-100%, preferably 95-100%, more preferably 100%.

"Stringent conditions" are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl/0.0015 M sodium titrate/0.1 %
5 NaDodSO₄ at 50°C, or (2) employ during hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin ("BSA")/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH
6.5 with 750 mM NaCl, 75 mM sodium citrate at 42°C. Another example is use of 50%
formamide, 5 x 0.75 M NaCl and 0.075 M sodium citrate ("SSC"), 50 mM sodium
10 phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 mg/ml), 0.1% sodium dodecyl sulfate ("SDS"), and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC and 0.1% SDS.

"Isolated" nucleic acid will be nucleic acid that is identified and separated from contaminant nucleic acid encoding other polypeptides from the source of nucleic acid.

15 The nucleic acid may be labeled for diagnostic and probe purposes, using any label known and described in the art as useful in connection with diagnostic assays.

Preferred Embodiments

The present invention relates to human type VI adenylyl cyclase, which is referred to herein as "hAC6". Figure 1 shows the DNA sequence of the clone encoding the hAC6
20 polypeptide along with the deduced amino acid sequence. As used herein, the terms "hAC6 polypeptide" or "hAC6 enzyme" refer to any adenylyl cyclase sharing a common biological activity with the human type VI adenylyl cyclase contained in the clone described in Example 1. This "common biological activity" includes but is not limited to an effector function or cross-reactive antigenicity.

25 As indicated above, type VI adenylyl cyclase is in the same isoform class as type VI, being expressed mainly in the heart and brain. As with the other known isoforms, type VI adenylyl cyclase has a similar putative structure: six extracellular domains; five intracellular domains, four small ones and a large cytoplasmic loop; and intracellular amino and carboxy termini.

However, type VI adenylyl cyclase, like type V, is distinguishable over other adenylyl cyclase isoforms in that it has a larger N-terminus and a relatively shorter C-terminus as it lacks the C_{2b} region. In the other mammalian isoforms (types I-V and VII-IX), much of the membrane associated secondary structure is well conserved.

5 Certain portions of the hAC6 polypeptide are similarly conserved.

The scope of the present invention is not limited to the exact sequence of the hAC6 cDNA set forth in Figure 1 (SEQ ID NO: 1), or the use thereof. The invention contemplates certain modifications to the sequence, including deletions, insertions, and substitutions, such as are well known to those skilled in the art. For example, the
10 invention contemplates replacing one or more codons in the cDNA sequence of Figure 1, with codons that encode amino acids that are chemically equivalent to the amino acids in the native protein. Chemical equivalency is determined, for example, by one or more of the following characteristics: hydrophobicity or hydrophilicity, charge, size, whether the residue is cyclic or non-cyclic, aromatic or non-aromatic. So, for example, a codon
15 encoding a neutral polar amino acid can be substituted with another codon that encodes a neutral polar residue, with the reasonable expectation of producing a biologically equivalent product.

Amino acid residues can be generally classified into four groups. Acidic residues are hydrophilic and have a negative charge due to loss of H⁺ at physiological pH. Basic
20 residues are also hydrophilic but have a positive charge due to association with H⁺ at physiological pH. Neutral nonpolar residues are hydrophobic and are not charged at physiological pH. Neutral polar residues are hydrophilic and are not charged at physiological pH. Amino acid residues can be further classified as cyclic or noncyclic, and aromatic or nonaromatic, self-explanatory classifications with respect to the side
25 chain substituent groups of the residues, and as small or large. The residue is considered small if it contains a total of 4 carbon atoms or less, inclusive of the carboxyl carbon. Small residues are, of course, always nonaromatic.

Of the naturally occurring amino acids, aspartic acid and glutamic acid are acidic; arginine and lysine are basic and noncyclic; histidine is basic and cyclic; glycine, serine
30 and cysteine are neutral, polar and small; alanine is neutral, nonpolar and small;

threonine, asparagine and glutamine are neutral, polar, large and nonaromatic; tyrosine is neutral, polar, large and aromatic; valine, isoleucine, leucine and methionine are neutral, nonpolar, large and nonaromatic; and phenylalanine and tryptophan are neutral, nonpolar, large and aromatic. Proline, although technically neutral, nonpolar, large, cyclic and
5 nonaromatic, is a special case due to its known effects on the secondary conformation of peptide chains, and is not, therefore, included in this defined group.

There are also commonly encountered amino acids, which are not encoded by the genetic code. These include, by way of example and not limitation: sarcosine, beta-alanine, 2,3-diamino propionic and alpha-aminisobutyric acid which are neutral,
10 nonpolar and small; *t*-butylalanine, *t*-butylglycine, N-methylisoleucine, norleucine and cyclohexylalanine which are neutral, nonpolar, large and nonaromatic; ornithine which is basic and noncyclic; cysteic acid which is acidic; citrulline, acetyl lysine, and methionine sulfoxide which are neutral, polar, large and nonaromatic; and phenylglycine, 2-naphthylalanine, β -2-thienylalanine and 1,2,3,4-tetrahydroisoquinoline-3-carboxylic
15 acid which are neutral, nonpolar, large and aromatic.

Ordinarily, the hAC6 polypeptide claimed herein will have an overall amino acid sequence having at least 75% amino acid sequence identity with the hAC6 sequence disclosed in Figure 1, more preferably at least 80%, even more preferably at least 90%, and most preferably at least 95%. More particularly, the N-terminus, C1b and C2b
20 regions of the hAC6 polypeptide or polypeptide fragment claimed herein, will have an amino acid sequence having at least 90%, and most preferably at least 95% amino acid sequence identity with the hAC6 sequence disclosed in Figure 1. Identity or homology with a sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the sequence of the hAC6 polypeptide, after
25 aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. N-terminal, C-terminal or internal extensions, deletions, or insertions of the hAC6 sequence shall be construed as affecting homology.

Thus, the claimed hAC6 polypeptide that is the subject of this invention includes
30 molecules having the hAC6 amino acid sequence; fragments thereof having a consecutive sequence of at least 10, 15, 20, 25, 30 or 40 amino acid residues from the hAC6

sequence of Figure 1, which exhibits the hAC6 polypeptide characteristics; amino acid sequence variants of the hAC6 sequence of Figure 1 wherein an amino acid residue has been inserted N- or C-terminal to, or within, (including parallel deletions) the hAC6 sequence or its fragments as defined above; amino acid sequence variants of the hAC6 sequence of Figure 1 or its fragments as defined above which have been substituted by at least one residue, and which exhibit the hAC6 polypeptide characteristics. Of particular interest are those peptides corresponding to those regions where the hAC6 polypeptide is divergent from types I-V and VII-IX.

Human type VI adenylyl cyclase polypeptides include those containing
10 predetermined mutations by, *e.g.*, homologous recombination, site-directed or PCR mutagenesis; naturally occurring variants of the hAC6 polypeptide; derivatives of the hAC6 polypeptide or its fragments wherein the hAC6 or its fragments have been covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid (for example a detectable moiety
15 such as an enzyme or radioisotope); glycosylation variants of the hAC6 (insertion of a glycosylation site or deletion of any glycosylation site by deletion, insertion or substitution of appropriate amino acid); and soluble forms of the hAC6 polypeptide or fragments thereof. This invention also includes tagging the hAC6 polypeptide, for example, for use in a diagnostic application. Types and methods of tagging are well
20 known in the art, for example, the use of hexa-histidine tags.

Several regions of the Type VI isoform are highly conserved with the other adenylyl cyclase isoforms. Accordingly, it is believed that most sequence modifications to the highly conserved regions such as the extracellular domains, transmembrane regions and short intracellular domains, including deletions and insertions, and substitutions in
25 particular, are not expected to produce radical changes in the characteristics of the hAC6 polypeptide, distinct from those found with similar changes to other isoforms. However, when it is difficult to predict the exact effect of the sequence modification in advance of making the change, one skilled in the art will appreciate that the effect of any sequence modification will be evaluated by routine screening assays.

30 The nomenclature used to describe the peptide compounds of the invention follows the conventional practice where the N-terminal amino group is assumed to be to the left

and the carboxy group to the right of each amino acid residue in the peptide. In the formulas representing selected specific embodiments of the present invention, the amino- and carboxy-terminal groups, although often not specifically shown, will be understood to be in the form they would assume at physiological pH values, unless otherwise specified.

5 Thus, the N-terminal H^+ and C-terminal O^- at physiological pH are understood to be present though not necessarily specified and shown, either in specific examples or in generic formulas. Free functional groups on the side chains of the amino acid residues can also be modified by amidation, acylation or other substitution, which can, for example, change the solubility of the compounds without affecting their activity. All of
10 the compounds of the invention, when an amino acid forms the C-terminus, may be in the form of the pharmaceutically acceptable salts or esters. Salts may be, for example, Na^+ , K^+ , Ca^{+2} , Mg^{+2} and the like; the esters are generally those of alcohols of 1-6 carbons.

In all of the peptides of the invention, one or more amide linkages ($-CO-NH-$) may optionally be replaced with another linkage which is an isostere such as $-CH_2NH-$,
15 $-CH_2S-$, $-CH_2CH_2-$, $-CH=CH-$ (cis and trans), $-COCH_2-$, $-CH(OH)CH_2-$ and $-CH_2SO-$. This replacement can be made by methods known in the art. The following references describe preparation of peptide analogs which include these alternative-linking moieties: Spatola, Vega Data 1(3) "Peptide Backbone Modifications" (general review) (March 1983); Spatola, in "Chemistry and Biochemistry of Amino Acids Peptides and Proteins,"
20 B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983) (general review); Morley, J.S., Trends Pharm Sci, pp. 463-468 (general review) (1980); Hudson, *et al.*, Int J Pept Prot Res 14:177-185 ($-CH_2NH-$, $-CH_2CH_2-$) (1979); Spatola, *et al.*, Life Sci 38:1243-1249 ($-CH_2S-$) (1986); Hann, J Chem Soc Perkin Trans I 307-314 ($-CH-CH-$, cis and trans) (1982); Almquist, *et al.*, J Med Chem 23:1392-1398 ($-COCH_2-$) (1980);
25 Jennings-White, *et al.*, Tetrahedron Lett 23:2533 ($-COCH_2-$) (1982); Szelke, *et al.*, European Application EP 45665 (1982) CA:97:39405 (1982) ($-CH(OH)CH_2-$); Holladay, *et al.*, Tetrahedron Lett 4:4401-4404 ($-C(OH)CH_2-$) (1983); and Hruby, Life Sci 31:189-199 ($-CH_2S-$) (1982).

Human type VI adenylyl cyclase peptides may be purified using techniques of
30 classical protein chemistry, such as are well known in the art. For example, a lectin affinity chromatography step may be used, followed by a highly specific ligand affinity

chromatography procedure that utilizes a ligand conjugated to biotin through the cysteine residues of the ligand. Alternately, the hexa-histidine tagged hAC6 polypeptide may be purified using nickel column chromatography.

One embodiment of the invention relates to recombinant materials associated with the production of the hAC6 polypeptide. One method of producing hAC6 comprises incorporating a nucleic acid having the nucleotide sequence of Figure 1 (SEQ ID NO:1) into an expression vector, transforming a host cell with the vector and culturing the transformed host cell under conditions which result in expression of the gene. Suitable expression vectors include pc3hAC6. Examples of host cells includes bacterial, viral, yeast, insect or mammalian cell lines. A preferred host cell is the human embryonic cell line referred to as "HEK-293".

The invention also contemplates the use of transfected cells that can be cultured so as to display or express hAC6 on its surface, thus providing an assay system for the interaction of materials with the native hAC6 where these cells or relevant fragments of hAC6 are used as a screening tool to evaluate the effect of various candidate compounds on hAC6 activity *in vivo*, as is described below. Another embodiment of the invention relates to recombinant materials associated with the production of soluble hAC6 fragments. These include transfected cells, such as *E. coli*, that can be cultured so as to express active portions of the hAC6 polypeptide, in particular the C1 and C2 (C-terminus) intracellular loops. These soluble fragments can be purified and reconstituted to obtain enzymatic activity. This has been demonstrated with like domains from other isoforms. See Whisnant, *et al.*, Proc. Natl. Acad. Sci.:93:6621-6625 (1996). Such soluble fragments can also be used as a screening tool to evaluate the effect of various candidate compounds on hAC6 activity. Suitable cells for transfection include bacterial cells, insect cells such as Sf-9 cells, yeast cells and most mammalian cell lines.

Recombinant production of the hAC6 polypeptide involves using a nucleic acid sequence that encodes hAC6, as is set forth in Figure 1, or its degenerate analogs. The nucleic acid can be prepared either by retrieving the native sequence, as described below, or by using substantial portions of the known native sequence as a probe, or it can be synthesized *de novo* using procedures that are well known in the art.

The nucleic acid may be ligated into expression vectors suitable for the desired host and then transformed into compatible cells. Suitable vectors suitable for use in transforming bacterial cells are well known in the art. Plasmids and bacteriophages, such as lambda phage, are commonly used as vectors for bacterial hosts such as *E. coli*. Virus
5 vectors are suitable for use in mammalian and insect cells for expression of exogenous DNA. Mammalian cells are readily transformed with SV40 or polyoma virus; and insect cells in culture may be transformed with baculovirus expression vectors. Suitable yeast vector systems include yeast centromere plasmids, yeast episomal plasmids and yeast integrating plasmids. Alternatively, nucleic acids may be introduced directly into a host
10 cell by techniques such as are well known in the art.

The cells are cultured under conditions favorable for the expression of the gene encoding the hAC6 polypeptide and cells displaying hAC6 on the surface are then harvested. Suitable eukaryotic host cells include mammalian cells, plant cells, yeast cells and insect cells. Suitable prokaryotic host cells, include bacterial cells such as *E. coli* and
15 *Bacillus subtilis*, Chinese Hamster Ovary cells, COS cells, the rat-2 fibroblast cell line, the human embryonic kidney 293 cell line, and insect cell lines such as Sf-9.

This invention also relates to nucleic acids that encode or are complementary to a hAC6 polypeptide. These nucleic acids can then be used to produce the polypeptide in recombinant cell culture for diagnostic use or for potential therapeutic use. In still other
20 aspects, the invention provides an isolated nucleic acid molecule encoding hAC6, either labeled or unlabeled, or a nucleic acid sequence that is complementary to, or hybridizes under stringent conditions to, a nucleic acid sequence encoding hAC6. The isolated nucleic acid molecule of the invention excludes nucleic acid sequences which encode, or are complementary to nucleic acid sequences encoding, other known adenyl cyclase
25 isoforms.

This invention also provides a replicable vector comprising a nucleic acid molecule encoding hAC6 operably linked to control sequences recognized by a host transformed by the vector; host cells transformed with the vector; and a method of using a nucleic acid molecule encoding hAC6 to effect the production of hAC6 on the cell surface or as
30 soluble fragments, comprising expressing the nucleic acid molecule in a culture of the

transformed host cells and recovered from the cells. The nucleic acid sequence is also useful in hybridization assays for hAC6-encoding nucleic acid molecules.

In still further embodiments of the invention, a method is described for producing hAC6 comprising inserting into the DNA of a cell containing the nucleic acid sequence
5 encoding hAC6, a transcription modulatory element (such as an enhancer or a silencer) in sufficient proximity and orientation to the hAC6-coding sequence to influence transcription thereof, with an optional further step comprising culturing the cell containing the transcription modulatory element and the hAC6-encoding nucleic acid sequence.

10 This invention also covers a cell comprising a nucleic acid sequence encoding the hAC6 polypeptide and an exogenous transcription modulatory element in sufficient proximity and orientation to the above coding sequence to influence transcription thereof and a host cell containing the nucleic acid sequence encoding hAC6 operably linked to exogenous control sequences recognized by the host cell.

15 This invention provides a method for obtaining cells having increased or decreased transcription of the nucleic acid molecule encoding the hAC6 polypeptide, comprising: providing cells containing the nucleic acid molecule; introducing into the cells a transcription modulating element; and screening the cells for a cell in which the transcription of the nucleic acid molecule is increased or decreased.

20 Human adenylyl cyclase type VI nucleic acids for use in the invention can be produced as follows. A hAC6 "nucleic acid" is defined as RNA or DNA that encodes the hAC6 polypeptide, or is complementary to nucleic acid sequence encoding hAC6, or hybridizes to such nucleic acid and remains stably bound to it under stringent conditions, or encodes a polypeptide sharing at least 75% sequence identity, preferably at least 80%,
25 and more preferably at least 85%, with the deduced amino acid sequence shown in Figure 1. It is typically at least about 10 nucleotides in length and preferably has hAC6 related biological or immunological activity. Specifically contemplated are genomic DNA, cDNA, mRNA and antisense molecules, as well as nucleic acids based on alternative backbone or including alternative bases whether derived from natural sources or
30 synthesized.

Of particular interest is a hAC6 nucleic acid that encodes a full-length molecule, including but not necessarily the native signal sequence thereof. Nucleic acid encoding full-length protein is obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using
5 conventional primer extension procedures to secure DNA that is complete at its 5' coding end. Such a clone is readily identified by the presence of a start codon in reading frame with the original sequence.

DNA encoding an amino acid sequence variant of the hAC6 polypeptide is prepared as described below or by a variety of methods known in the art. These methods
10 include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of hAC6.

Techniques for isolating and manipulating nucleic acids are disclosed for example
15 by the following documents: U.S. Patent No. 5,030,576, U.S. Patent No. 5,030,576 and International Patent Publications WO94/11504 and WO93/03162. See, also, Sambrook, *et al.*, "Molecular Cloning: A Laboratory Manual", 2nd Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989, and Ausubel, *et al.*, "Current Protocols in Molecular Biology", Vol. 2, Wiley-Interscience, New York, 1987.

20 The isolation, recombinant production and characterization of the hAC6 polypeptide allows for the design of assay systems using hAC6. The availability of the isolated cells providing hAC6 on their surface and the availability of the recombinant DNA encoding hAC6 which permits display and expression of the enzyme on host cell surfaces, all makes such cells available as a valuable tool for evaluating the ability of
25 candidate pharmaceuticals, both agonists and antagonists, to affect the activity of hAC6. In this manner, the invention is related to assay systems which utilize isolated or recombinantly produced hAC6 to screen for agonist and antagonist activity of candidate drugs. This assay is especially useful in assuring that these candidate therapeutic agents have the desired effect on hAC6. Determination of these properties is essential in
30 evaluating the specificity of drugs for other adenylyl cyclase isoforms.

The host cells are typically animal cells, most typically mammalian cells. In order to be useful in the assays, the cells must have intracellular mechanisms which permit hAC6 to be displayed on the cell surface or to be expressed as soluble fragments. The animal host cells expressing the DNA encoding the hAC6 polypeptide or a fragment thereof are then cultured to effect the expression of the encoding nucleic acids so as to either 1) produce hAC6 display on the cell surface such that the cells can then be used directly in assays for assessment of a candidate drug to bind to or otherwise affect the activity of the enzyme, or 2) produce hAC6 as soluble fragments which can then be purified and reconstituted to obtain an enzymatically active compound useful in screening assays.

There are several possible strategies to identify compounds which affect hAC6 activity. Over expression of the hAC6 cDNA can provide a means for isolation of large quantities of crude membrane preparations from a stable cell line. HEK-293 cells have been found to be particularly useful for this purpose. In this system the measurable enzyme activity would be predominantly from expression of recombinant hAC6. A highly sensitive, reproducible, high throughput screening system is desirable, with enzyme activity detected in a 96 well, scintillation proximity-type assay to measure product formation (cAMP). There are numerous screening assays that can be utilized. For example, the basal (unstimulated) activity of hAC6 can be measured as a method of detecting both agonists and antagonists of the hAC6 enzyme. In addition, stimulation of the enzyme by its most relevant physiological activator, the heterotrimeric G protein subunit, $G_{\alpha s}$, can be assayed using activated (GTP γ S bound) recombinant bovine $G_{\alpha s}$ (expressed and purified from bacteria), with the expectation that additional compounds may be identified which inhibit $G_{\alpha s}$ stimulation of the hAC6 polypeptide. Other stimulatory agents can also be used, such as forskolin or forskolin analogs. "Hits", i.e., compounds which affect hAC6, in any of these screens will be further evaluated in other assays to help focus on compounds which are relevant to the targeted isoform.

Another method of evaluating candidates as potential therapeutic agents typically involves a screening based approach such as a binding assay in which the candidate (such as a peptide or a small organic molecule) would be tested to measure if, or to what extent, it binds the catalytic subunit of the hAC6 enzyme. Preferably, a mammalian cell line that

expresses recombinant hAC6 or plasma membrane preparations thereof, will be used in the assay. For example, a candidate antagonist competes for binding to hAC6 with either a labeled agonist or antagonist, for example labeled forskolin or a labeled forskolin analog. Varying concentrations of the candidate are supplied, along with a constant
5 concentration of the labeled agonist or antagonist. The inhibition of binding of the labeled material can then be measured using established techniques. This measurement is then correlated to determine the amount and potency of the candidate that is bound to hAC6.

Another method of identifying compounds which affect hAC6 activity is the
10 rational design of synthetic compounds based on nucleotide scaffolds, targeted to either of two distinct sites on the hAC6 enzyme. One of these is the active site (ATP being the substrate, cAMP being the product) and the other is the separate P site (adenine nucleoside 3'-polyphosphates reportedly demonstrating the greatest inhibitory activity, with either pure or crude enzyme preparations). As a related approach, one could attempt
15 to design forskolin analogues which may demonstrate isoform specific effects.

In addition, using the above assays, the ability of a candidate drug to stimulate or inhibit the activity of hAC6 can be tested directly.

Once lead candidates are identified, and for purposes of demonstrating that isoform
specificity may be achieved with small molecule modulators, it is desirable to develop
20 assay systems which monitor most, and preferably all, human adenylyl cyclase isoforms. These assays may be used to evaluate either existing (e.g. forskolin analogs or P site inhibitors) or newly discovered small molecule modulators and determine structure activity relationships for different adenylyl cyclase isoforms. Such assays could also be used to evaluate either specific or selective modulators of other adenylyl targets and with
25 use of a whole cell assay, may provide useful insights for designing bioavailability and addressing biological activity of lead candidates.

The hAC6 also has utility in assays for the diagnosis of diseases and disorders by detection, in tissue samples, of aberrant expression of the hAC6 enzyme.

Another aspect of the invention relates to hAC6 agonists that imitate the naturally
30 occurring form of hAC6. These agonists are useful as control reagents in the

above-mentioned assays to verify the workability of the assay system. In addition, agonists for hAC6 may exhibit useful effects *in vivo* in treating disease.

Another aspect of the invention relates to hAC6 antagonists that are modified forms of hAC6 peptides. Such antagonists bind to hAC6, and prevent enzyme-substrate
5 interaction by blocking their binding to hAC6. Another group of compounds within the scope of the invention, are antagonists of hAC6 substrate, i.e., these are substrate inhibitors. Both these types of antagonists find utility in diminishing or mediating events based upon enzyme-substrate interaction such as cAMP production. Yet another second group of antagonists includes antibodies designed to bind specific portions of hAC6. In
10 general, these are monoclonal antibody preparations which are highly specific for any desired region of hAC6, although polyclonal antibodies are also contemplated by this invention. The antibodies, which are explained in greater detail below, are also useful in immunoassays for the hAC6 enzyme, for example, in assessing successful expression of the gene in recombinant systems.

15 In both the agonists and antagonists, a preferred embodiment is that class of compounds having amino acid sequences that are encoded by the hAC6 gene. The invention also includes those compounds where one, two, three or more of said amino acid residues are replaced by one(s) which is not encoded genetically. Also included in the invention are isolated DNA molecules that encode these specific peptides.

20 It is believed that the extracellular domains of enzymes may play a key role in extracellular activities, for example, in enzyme regulation. Accordingly, the invention includes agonists and antagonists having amino acid sequences, in whole or in part, corresponding to the extracellular domains of hAC6, the sequences of which can be approximated from the amino acid sequence of Figure 1 and the hydropathy analysis of
25 Figure 4. The invention also includes agonists and antagonists that affect the enzyme's function by binding to the N- or C-terminus or to one of the intracellular (ICD) domains of hAC6, the sequences of which can be approximated from the amino acid sequence of Figure 1 and the hydropathy analysis.

In other adenylyl cyclases, the ICD IV and carboxy terminus regions have been
30 shown to play a role in enzyme activity or G_s or forskolin interaction. See for example: Whisnant, *et al.*, *supra*. Accordingly, it is expected that the amino acid sequences of the

ICD IV and carboxy terminus regions of hAC6, in whole or in part, will be particularly useful in designing antibodies or peptides that can bind the enzyme and block enzyme activity or $G_{\alpha s}$ interaction.

As the understanding of adenylyl cyclases and factors which effect isoform activity increases, rational drug design is becoming a viable alternative in pharmaceutical research. It is believed that the two conserved intracellular domains of adenylyl cyclase (the C_1 and C_2 domains) associate to form an active enzyme. This has been demonstrated with studies that combine both expressed recombinant C_1 and C_2 domains. Both the C_1 and C_2 domains are required to reconstitute enzyme activity while either alone has no substantial activity. Forskolin plus $G_{\alpha s}$ stimulates this system, by increasing the association of the two domains. Designing assays which monitor enzyme activity, dependent on association of two separate domains, is expected to provide greater sensitivity to antagonists since this would presumably be more easily disrupted. Other studies have demonstrated that peptides, comprised of sequences from conserved regions of the intracellular domains, act as inhibitors of detergent solubilized enzyme preparations. This invention contemplates the use of peptide walking strategies, to delimit regions of the modulator which may be responsible for its activity, leading to the design of small molecule inhibitors. Finally, knowledge of uncharacterized, physiological modulators of adenylyl cyclase, particularly those that demonstrate isoform specificity, may provide new assay systems for identifying novel AC modulators. It is expected that many of these modulators would be proteins and some may be identified while using adenylyl cyclase sequences as "bait" in a yeast two hybrid system. Alternatively one may identify proteins which coprecipitate with adenylyl cyclase upon capture with adenylyl cyclase antibodies.

The peptide agonists and antagonists of the invention are preferably about 10-100 amino acids in length, more preferably 25-75 amino acids in length. These peptides can be readily prepared using standard solid phase or solution phase peptide synthesis, as is well known in the art. In addition, the DNA encoding these peptides can be synthesized using commercially available oligonucleotide synthesis instrumentation and recombinantly produced using standard recombinant production systems. Production using solid phase

peptide synthesis is required when non-gene encoded amino acids are to be included in the peptide.

Another aspect of the invention pertains to antibodies, which have both diagnostic and therapeutic uses. Antibodies are able to act as antagonists or agonists by binding
5 specific regions of the hAC6 polypeptide. These antibodies also find utility in immunoassays that measure the presence of hAC6, for example in immunoassays that measure gene expression. In general, antibodies to adenylyl cyclases, and more importantly, those which may recognize specific isoforms of adenylyl cyclase, are a useful tool to evaluate tissue distribution and prevalence of the adenylyl cyclase protein.
10 By identifying regions of dissimilarity between the adenylyl cyclase isoforms and the antigenic potential of these regions, either synthetic peptides or recombinant proteins to these sequences can be created for use in immunization. The resulting antibodies would then be characterized for specificity based on the unique qualities of the immunogen and reactivity with other expressed isoforms. Detection of isoform protein in various tissues
15 can readily be monitored by Westerns blots; however, immunohistochemical analysis would also be useful. This information is useful to identify the adenylyl cyclase target of interest, providing valuable insights into useful therapeutic strategies such as targets in cardiovascular disease, asthma or obesity.

The antibodies of the present invention can be prepared by techniques that are well
20 known in the art. The antibodies can be monoclonal or polyclonal, but are preferably monoclonal antibodies that are highly specific for hAC6 and can be raised against the whole hAC6 polypeptide or regions thereof. Antibodies are prepared by immunizing suitable mammalian hosts (typically rabbit, rat, mouse, goat, human, etc.) in appropriate immunization protocols using the peptide haptens (immunogen) alone, if they are of
25 sufficient length, or, if desired, or if required to enhance immunogenicity, conjugated to suitable carriers. The immunogen will typically contain a portion of the hAC6 polypeptide that is intended to be targeted by the antibodies. Critical regions include those regions corresponding to the extracellular domains of the hAC6 enzyme, any region(s) of proteolytic cleavage, and any segment(s) of the extracellular segment critical
30 for activation. Methods for preparing immunogenic conjugates with carriers such as bovine serum albumin, keyhole limpet hemocyanin, or other carrier proteins are well

known in the art. In some circumstances, direct conjugation using, for example, carbodiimide reagents may be effective; in other instances linking reagents such as those supplied by Pierce Chemical Co., Rockford, IL, may be desirable to provide accessibility to the hapten. The hapten can be extended at the amino or carboxy terminus with a cysteine residue or interspersed with cysteine residues, for example, to facilitate linking to carrier. The desired immunogen is administered to a host by injection over a suitable period of time using suitable adjuvants followed by collection of sera. Over the course of the immunization schedule, titers of antibodies are taken to determine the adequacy of antibody formation.

10 Polyclonal antibodies are suitable for many diagnostic and research purposes and are easily prepared. Monoclonal antibodies are often preferred for therapeutic applications and are prepared by continuous hybrid cell lines and collection of the secreted protein. Immortalized cell lines that secrete the desired monoclonal antibodies can be prepared by the method described in Kohler and Milstein, Nature 256:495-497
15 (1975) or modifications which effect immortalization of lymphocytes or spleen cells, as is generally known. The immortalized cell lines are then screened by immunoassay techniques in which the antigen is the immunogen or a cell expressing hAC6 on its surface. Cells that are found to secrete the desired antibody, can then be cultured *in vitro* or by production in the ascites fluid. The antibodies are then recovered from the culture
20 supernatant or from the ascites supernatant.

Alternately, antibodies can be prepared by recombinant means, i.e., the cloning and expression of nucleotide sequences or mutagenized versions thereof that at a minimum code for the amino acid sequences required for specific binding of natural antibodies. Antibody regions that bind specifically to the desired regions of hAC6 can
25 also be produced as chimeras with regions of multiple species origin.

Antibodies may include a complete immunoglobulin or a fragment thereof, and includes the various classes and isotypes such as IgA, IgD, IgE, IgG1, IgG2a, IgG2b, IgG3 and IgM. Fragments include Fab, Fv, F(ab')₂, Fab', and so forth. Fragments of the monoclonals or the polyclonal antisera which contain the immunologically significant
30 portion can be used as antagonists, as well as the intact antibodies. Use of immunologically reactive fragments, such as the Fab, Fab', or F(ab')₂ fragments is often

preferable, especially in a therapeutic context, as these fragments have different immunogenicity than the whole immunoglobulin, and do not carry the biological activity of an immunoglobulin constant domain.

The antibodies thus produced are useful not only as potential agonist or antagonists for the hAC6 polypeptide, filling the role of agonist or antagonist in the assays of the invention, but are also useful in immunoassays for detecting the hAC6 enzyme. As such these antibodies can be coupled to imaging agents for administration to a subject to allow detection of localized antibody to ascertain the under-or over-expression of hAC6 in tissues of interest. In addition, these reagents are useful in vitro to detect, for example, the successful production of hAC6 on the surface of the recombinant host cells.

Yet another aspect of the invention relates to pharmaceutical compositions containing the compounds and antibodies of the invention. The agonists and antagonists of the invention have therapeutic utility in (1) treating diseases caused by aberrant activity of the hAC6 enzyme in tissues where it is customarily found, for example in the heart and brain and (2) treating diseases whose symptoms can be ameliorated by stimulating or inhibiting the activity of hAC6.

The peptide agonists and antagonists of the invention can be administered in conventional formulations for systemic administration such as is well known in the art. Typical formulations may be found, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton PA, latest edition.

Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can also be used. More recently, alternative means for systemic administration of peptides have been devised which include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if properly formulated in enteric or encapsulated formulations, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels and the like.

The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the patient's condition, and the judgment of the attending physician. Suitable dosage ranges, however, are in the range of 0.1-100 $\mu\text{g/kg}$ of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of peptides available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization as is well understood in the art.

10 The invention also relates to the therapeutic, prophylactic and research uses of various techniques to block or modulate the expression of the hAC6 by interfering with the transcription or translation of a DNA or RNA molecule encoding the hAC6. This includes a method to inhibit or regulate expression of hAC6 in a cell comprising providing to the cell an oligonucleotide molecule which is antisense to, or forms a triple
15 helix with, hAC6-encoding DNA or with DNA regulating expression of hAC6-encoding DNA, in an amount sufficient to inhibit or regulate expression of the hAC6, thereby inhibiting or regulating its expression. Also included is a method to inhibit or regulate expression of hAC6 in a subject, comprising administering to the subject an oligonucleotide molecule which is antisense to, or forms a triple helix with,
20 hAC6-encoding DNA or with DNA regulating expression of hAC6-encoding DNA, in an amount sufficient to inhibit or regulate expression of hAC6 in the subject, thereby inhibiting or regulating its expression. The antisense molecule or triple helix-forming molecule in the above methods is preferably a DNA or RNA oligonucleotide. These utilities are described in greater detail below.

25 The constitutive expression of antisense RNA in cells has been shown to inhibit the expression of about 20 different genes in mammals and plants, and the list continually grows (Hambor, *et al.*, J. Exp. Med. 168:1237-1245 (1988); Holt, *et al.*, Proc. Natl. Acad. Sci. 83:4794-4798 (1986); Izant, *et al.*, Cell 36:1007-1015 (1984); Izant, *et al.*, Science 229:345-352 (1985) and De Benedetti, *et al.*, Proc. Natl. Acad. Sci. 84:658-662
30 (1987)). Possible mechanisms for the antisense effect are the blockage of translation or

prevention of splicing, both of which have been observed in vitro. Interference with splicing allows the use of intron sequences (Munroe, EMBO J. 7:2523-2532 (1988) which should be less conserved and therefore result in greater specificity in inhibiting expression of a protein of one species but not its homologue in another species.

5 Therapeutic gene regulation is accomplished using the "antisense" approach, in which the function of a target gene in a cell or organism is blocked, by transfection of DNA, preferably an oligonucleotide, encoding antisense RNA which acts specifically to inhibit expression of the particular target gene. The sequence of the antisense DNA is designed to result in a full or preferably partial antisense RNA transcript which is

10 substantially complementary to a segment of the gene or mRNA which it is intended to inhibit. The complementarity must be sufficient so that the antisense RNA can hybridize to the target gene (or mRNA) and inhibit the target gene's function, regardless of whether the action is at the level of splicing, transcription or translation. The degree of inhibition, readily discernible by one of ordinary skill in the art without undue experimentation, must

15 be sufficient to inhibit, or render the cell incapable of expressing, the target gene. One of ordinary skill in the art will recognize that the antisense RNA approach is but one of a number of known mechanisms which can be employed to block specific gene expression.

By the term "antisense" is intended an RNA sequence, as well as a DNA sequence coding therefor, which is sufficiently complementary to a particular mRNA molecule for

20 which the antisense RNA is specific to cause molecular hybridization between the antisense RNA and the mRNA such that translation of the mRNA is inhibited. Such hybridization must occur under in vivo conditions, that is, inside the cell. The action of the antisense RNA results in specific inhibition of gene expression in the cell. See Albers, *et al.*, "Molecular Biology Of The Cell", 2nd Ed., Garland Publishing, Inc., New

25 York, NY (1989), in particular, pages 195-196.

The antisense RNA of the present invention may be hybridizable to any of several portions of a target mRNA, including the coding sequence, a 3' or 5' untranslated region, or other intronic sequences. A preferred antisense RNA is that complementary to hAC6 mRNA. As is readily discernible by one of skill in the art, the minimal amount of

30 homology required by the present invention is that sufficient to result in hybridization to

the specific target mRNA and inhibition of its translation or function while not affecting function of other mRNA molecules and the expression of other genes.

Antisense RNA is delivered to a cell by transformation or transfection with a vector into which has been placed DNA encoding the antisense RNA with the appropriate regulatory sequences, including a promoter, to result in expression of the antisense RNA in a host cell.

"Triple helix" or "triplex" approaches involve production of synthetic oligonucleotides which bind to the major groove of a duplex DNA to form a colinear triplex. Such triplex formation can regulate and inhibit cellular growth. See, for example, Hogan, *et al.*, U.S. Patent 5, 176,996; Cohen, *et al.*, Sci. Amer., Dec. 1994, p. 76-82; Helene, Anticancer Drug Design 6:569-584 (1991); Maher III, *et al.*, Antisense Res. Devel. 1:227-281 (Fall 1991); and Crook, *et al.* eds., "Antisense Research and Applications", CRC Press, 1993; all of which are incorporated herein by reference. It is based in part on the discovery that a DNA oligonucleotide can bind by triplex formation to a duplex DNA target in a gene regulatory region, thereby repressing transcription initiation (Cooney, *et al.* Science 241:456 (1988)). The present invention utilizes methods such as those of Hogan *et al.*, *supra*, to designing oligonucleotides which will bind tightly and specifically to a duplex DNA target comprising part of the hAC6-encoding DNA or a regulatory sequence thereof. Such triplex oligonucleotides can therefore be used as a class of drug molecules to selectively manipulate the expression of this gene.

Thus the present invention is directed to providing to a cell or administering to a subject a synthetic oligonucleotide in sufficient quantity for cellular uptake and binding to a DNA duplex of the target hAC6-coding DNA sequence or a regulatory sequence thereof, such that the oligonucleotide binds to the DNA duplex to form a colinear triplex. This method is used to inhibit expression of the hAC6 enzyme on cells *in vitro* or *in vivo*. Preferably the target sequence is positioned within the DNA domain adjacent to the RNA transcription origin. This method can also be used to inhibit growth of cells which is dependent on expression of this enzyme. The method may also be used to alter the relative amounts or proportions of the hAC6 expressed on cells or tissues by administering such a triplex-forming synthetic oligonucleotide.

The following examples are intended to illustrate but not to limit the invention.

EXAMPLE 1

Construction and Screening of a human heart cDNA library

Whole human heart was used as a source of mRNA. The libraries were purchased
5 from a commercial source, Clontech (Catalog No. HL3026a). The libraries were
prepared in a lambda gt10 phage with both oligo-dT and random primers. The primary
screening of the lambda gt10 library was carried out with gentle washing (less stringent
conditions). Prehybridization and hybridization were carried out at standard conditions.
A suitable PCR AC fragment was used as a probe.

10 The probe was radiolabeled with ^{32}P -dCTP by the random primer labeling method.
After hybridization, the blot was washed under increasingly stringent conditions and then
radioautographed. A positive clone was obtained.

The next step was to ascertain the full length cDNA sequence from the inserts in
the clones. All the positive clones from the human heart library were subcloned into a
15 suitable plasmid. After restriction maps were made, they were further subcloned and
sequenced with universal primers or synthesized oligomers. The sequence was performed
bidirectionally with Sequenase (Tabor, *et al.*, Proc. Natl. Acad. Sci. USA 84:4767-4771
(1987)).

Clone were either used on their own, or sequenced and then used to generate PCR
20 primers which were used to acquire additional clones of interest, by the PCR-based
RACE ("rapid amplification of cDNA ends") technique (Frohman, M.A., Methods
Enzymol. 218:340-362 (1991)) and human heart mRNA. One clone of particular interest
was used as a probe to screen a separate human heart library and several more clones
were obtained. Sequencing revealed an open reading frame of 3504 bases reads through
25 to a TGA, a translation termination codon (Figure 1). Thus, the clone(s) encode a protein
of 1168 amino acids. The entire coding portion of the cDNA and its deduced amino acid
sequence are shown (Figure 1) (SEQ ID NO: 1 and 2, respectively).

One or more fragments from these clones were subcloned into pcDNA3, obtained
from Invitrogen. The resulting expression vector, containing the full length cDNA, was
30 given a designation. Samples of this expression vector, inserted into an appropriate *E.*
coli strain designated SURE, were deposited with the American Type Culture Collection,

12301 Parklawn Drive, Rockville, Md. 20852, on _____, 1997 in accordance with the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and have been accorded accession number ATCC _____.

5

EXAMPLE 2

Cloning and Expression of the human type VI adenylyl cyclase

The human type VI adenylyl cyclase was produced by cloning and expressing heart type VI adenylyl cyclase cDNA in a suitable expression system using recombinant DNA methods, such as are well known in the art.

10 Purified plasmid was transfected into HEK-293 cells using electroporation. The cells were grown in an appropriate growth medium then washed. After the addition of trypsin solution, the cells were incubated, harvested and resuspended in the growth media. Purified plasmid was added to an electroporation cuvette. Cells were added to the DNA and the mixture was pulsed. The cell-DNA mixture was then plated into a
15 suitable growth media. The plate was incubated before placing cells on a suitable selective media.

hAC6, having 1168 amino acids, was analyzed for secondary structure by the method of Kyte, *et al.*, J. Mol. Biol. 157:105-132 (1982). The software, GeneWorks; v.2.45; IntelliGenetics, Inc. ; Mountain View; California was used to obtain a hydropathy
20 plot, and thereby identify the membrane related structure of this adenylyl cyclase isoform. The method of Kyte, *et al.*, *supra*, was used with a window size of 5.

Twelve peaks appear in the hydropathy plot, not shown, which represent transmembrane spanning regions. These results suggest that this adenylyl cyclase isoform has a structure of twelve transmembrane spanning regions, as well as a large cytoplasmic
25 loop located in the middle and at the end, which is consistent with the structures of the previously characterized isoforms.

EXAMPLE 3

Evaluation of the human type VI adenylyl cyclase

The biochemical characteristics of hAC9 were determined in a stable expression
30 system using HEK-293 cells. A fragment of the adenylyl cyclase cDNA containing the whole coding sequence was inserted into a suitable plasmid.

An assay was performed to measure cAMP product formation and it was determined that the hAC6 enzyme expressed by this cDNA was active.

EXAMPLE 4

Tissue distribution of the human type VI adenylyl cyclase

5 In order to determine the tissue distribution of hAC6, Northern blotting was performed using mRNA from various tissues. Messenger RNA was purified using guanidium sodium and oligo-dT columns from various human tissues.

The blot was pre-hybridized in a suitable solution before the addition of a probe. Hybridization was performed, followed by washing under increasingly stringent
10 conditions. The blot was then autoradiographed.

The results of the Northern blot analysis indicated that hAC6 is predominantly expressed in heart and brain tissue, although some expression was also found at slight levels in other tissues.

All references cited and mentioned above, including patents, journal articles and
15 texts, are all incorporated by reference herein, whether expressly incorporated or not.

Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation.

20 While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the
25 invention pertains and as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims.

Claims

What is claimed is:

1. An isolated and purified human type VI adenylyl cyclase polypeptide comprising the amino acid sequence of Figure 1 (SEQ ID NO:2).
2. An isolated and purified nucleic acid encoding for human type VI adenylyl cyclase.
3. An isolated and purified nucleic acid comprising the nucleotide sequence of Figure 1 (SEQ ID NO:1), which encodes a biologically active human type VI adenylyl cyclase.
4. The nucleic acid of Claim 3, which encodes a biologically active soluble human type VI adenylyl cyclase peptide fragment.
5. A method of producing human type VI adenylyl cyclase which comprises incorporating the nucleic acid of claim 2 into an expression vector, transforming a host cell with said vector and culturing the transformed host cell under conditions which result in expression of the gene.
6. The method of claim 5 wherein the host cell comprises a bacterial, viral, yeast, insect or mammalian cell line.
7. The method of Claim 6 wherein said host cells are HEK-293 cells.

FIG. 1A

1/9

GCGGACGGCG GACGGGGGAC GCGGGGGGGG ACGGCCAGGA CCGCGGGGCT 50
 CGCTGCGCGC CTGCGCGCTG CCGCGCGGCC TGCGGGTGCT GCGCGCGCGA

CCGAGGACCG CCGGACGGCC GCGCGGGGGG CCGGAGCGCG CCGGGGGGGC 100
 GCGTCTGCGC GCGCTGCGCG CCGGCGGGCC GCGCTCGGGC GCGCGCGCGC

GGGGGGGGGG CCCAGGGCAG GCGCGGAGCC GGGCGGGCAG CAACATGTCA 150
 CCGCGCGCGC GGGTCCCGTC CCGCGCTCGG CCGGCGCGTC GTTGTACAGT
 MetSer

TGGTTTAGTG GCGTCTGGT CCCTAAAGTG GATGAACGGA AAACAGCGCTG 200
 ACCAAATCAC CCGAGGACCA GGGATTTCAC CTACTTGCGT TTGTGCGGAC
 TrpPheSerG lyLeuLeuVa lProLysVal AspGluArgL ysThrAlaTr

GGGTGAACGC AATGGGCAGA AGCGTTCGCG GCGCGGTGGC ACTCGGGCAG 250
 CCCACTTGCG TTACCGGTCT TCGCAAGCGC CCGGGCACCG TGAGCGCGTC
 pGlyGluArg AsnGlyGlnL ysArgSerAr gArgArgGly ThrArgAlaG

GTGGCTTCTG CACGCGCGCG TATATGAGCT GCGTCCGGGA TGCAGAGCCA 300
 CACCGAAGAC GTGCGGGGCG ATATACTCGA CCGAGGCGCT ACGTCTCGGT
 lyGlyPheCy sThrProArg TyrMetSerC ysLeuArgAs pAlaGluPro

CCCAGCCCCA CCGCTGCGGG CCGCGCTCGG TGCGCGTGGC AGGATGACGC 350
 GGGTCCGGGT GGGGACGCCC GGGGGGAGCC ACGGGGAACG TCCTACTGCG
 ProSerProT hrProAlaGl yProProArg CysProTrpG lnAspAspAl

CTTCATCCGG AGGGGCGGCC CAGGCAAGGG CAAGGAGCTG GGGCTGCGGG 400
 GAAGTAGGCC TCGCGCGCGG GTCCGTTCCT GTTCTCTGAC CCGGACGCCC
 aPheIleArg ArgGlyGlyP roGlyLysGl yLysGluLeu GlyLeuArgA

CAGTGGCCCT GGGCTTCGAG GATACCGAGG TGACAACGAC AGCGGGCGGG 450
 GTCACCGGGA CCGGAAGCTC CTATGGCTCC ACTGTTCGCT TCGCGCGGCC
 laValAlaLe uGlyPheGlu AspThrGluV alThrThrTh rAlaGlyGly

ACGGCTGAGG TGGCGCGCGA CCGGGTGGCC AGGAGTGGGA GATCCTGCTG 500
 TGCGGACTCC ACCGCGGGCT GCGCCACGGG TCCTCACCGT CTAGGAACGAC
 ThrAlaGluV alAlaProAs pAlaValPro ArgSerGlyA rgSerCysTr

GCGCGGTCTG GTGCAGGTGT TCCAGTCGAA GCAGTTCGGT TCGGCAAGC 550
 CCGGGCAGAC CACGTCCACA AGGTACGCTT CGTCAAGGCA AGCGGGTTCG
 pArgArgLeu ValGlnValP heGlnSerLy sGlnPheArg SerAlaLysL

TGGAGCACCT GTACCAGCGG TACTTCTTCC AGATGAACCA GAGCAGCGCTG 600
 ACCTCGTGGG CATGGTCGCC ATGAAGAAGG TCTACTTGGT CTCGTGCGAC
 euGluHisLe uTyrGlnArg TyrPhePheG lnMetAsnGl nSerSerLeu

FIG. 1B

2/9

ACCGTGCTGA TGGCGGTGCT GGTGCTGCTC ACAGCGGTGC TGCTGGCTTT 650
 TGGACGACT ACCGCCACGA CCACGACGAG TGTGCCACG ACGACCGAAA
 ThrLeuLeuM etAlaValLe uValLeuLeu ThrAlaValL euLeuAlaPh

 CCACGCCGCA CCCGCCCGCC CTCAGCCTGC CTATGTGGCA CTGTTGGCCT 700
 GGTGCGGCGT GGGCGGGCGG GAGTCGGACG GATACACCGT GACAACCGGA
 eHisAlaAla ProAlaArgP roGlnProAl aTyrValAla LeuLeuAlaC

 GTGCCGCCGC CCTGTTCGTG GGGCTCATGG TGGTGTGTAA CCGGCATAGC 750
 CACGCGGCGG GGACAAGCAC CCCGAGTACC ACCACACATT GCGCGTATCG
 ysAlaAlaAl aLeuPheVal GlyLeuMetV alValCysAs nArgHisSer

 TTCCGCCAGG ACTCCATGTG GGTGGTGGAG TACGTGGTGC TGGGCATCCT 800
 AAGGCGGTCC TGAGGTACAC CCACCACTCG ATGCACCACG ACCCGTAGGA
 PheArgGlnA spSerMetTr pValValSer TyrValValL euGlyIleLe

 GCGGCGAGTG CAGGTGGGGG GCGCTCTCGC AGCAGACCCG CGCAGCCCT 850
 CCGCGGTACG GTCCAGCCCC CGCGAGAGCG TCGTCTGGGC GCGTCGGGGA
 uAlaAlaVal GlnValGlyG lyAlaLeuAl aAlaAspPro ArgSerProS

 CTGCGGGCCT CTGGTGGCCT GTGTCTCTTG TCTACATCGC CTACACGCTC 900
 GACGCCCCGA GACCACGGGA CACAAGAAAC AGATGTAGCG GATGTGCGAG
 erAlaGlyLe uTrpCysPro ValPhePheV alTyrIleAl aTyrThrLeu

 CTCCCCATCC GCATGCGGGC TGCCGTCTTC AGCGGCCTGG GCCTCTCCAC 950
 GAGGGGTAGG CGTACGCCCC ACGGCAGGAG TCGCCGGACC CGGAGAGGTG
 LeuProIleA rgMetArgAl aAlaValLeu SerGlyLeuG lyLeuSerTh

 CTTCGATTTG ATCTTGGCCT GGCAACTTAA CCGTGGTGAT GCCTTCCTCT 1000
 GAACGTAAAC TAGAACCGGA CCGTTGAATT GGCACCACTA CGGAAGGAGA
 rLeuHisLeu IleLeuAlaT rpGlnLeuAs nArgGlyAsp AlaPheLeuT

 GGAAGCAGCT CCGTGCCAAT GTGCTGCTGT TCCTCTGCAC CAACGTCATT 1050
 CCTTCGTGCA GCCACGGTTA CACGACGACA AGGAGACGTG GTTGCAGTAA
 rpLysGlnLe uGlyAlaAsn ValLeuLeuP heLeuCysTh rAsnValIle

 GGCATCTGCA CACACTATCC AGCAGAGGTG TCTCAGCGCC AGGCCTTTCA 1100
 CCGTAGACGT GTGTGATAGG TCGTCTCCAC AGAGTCGGG TCCGGAAGT
 GlyIleCyst hrHisTyrPr oAlaGluVal SerGlnArgG lnAlaPheGl

 GGAGACCCGC GGTTACATCC AGGCCCGGCT CCACCTGCAG CATGAGAATC 1150
 CCTCTGGGCG CCAATGTAGG TCCGGGCGGA GGTGGACGTC GTACTCTTAG
 nGluThrArg GlyTyrIleG lnAlaArgLe uHisLeuGln HisGluAsnA

 GGCAGCAGGA GCGGCTGCTG CTGTGGTAT TGCCCCAGCA CGTTGCCATG 1200
 CCGTCGTCTT CCGCGACGAC GACAGCCATA ACGGGGTGCT GCAACGGTAC
 rgGlnGlnGl uArgLeuLeu LeuSerValL euProGlnHi sValAlaMet

SUBSTITUTE SHEET (RULE 26)

FIG. 1C

3/9

GAGATGAAAG AAGACATCAA CACAAAAAAA GAAGACATGA TGTTCACAA 1250
 CTCTACTTTC TICTIGTAGT GTGTTTTTTT CTCTGTACT ACAAGGIGTT
 GluMetLysG luAspIleAs nThrLysLys GluAspMetM etPheHisLy

 GATCTACATA CAGAAGCATG ACAATGTCAG CATCCTGTTT GCAGACATTG 1300
 CTAGATGTAT GICTTCGTAC TGTTACAGTC GTAGGACAAA CGTCTGTAAC
 sIleTyrIle GlnLysHisA spAsnValSe rIleLeuPhe AlaAspIleG

 AGGGCTTCAC CAGCCTGGCA TCCCAGTGCA CTGCGCAGGA GCTGGTCATG 1350
 TCCCGAAGTG GTCCGACCGT AGGGTCACGT GACCGGTCTT CGACCAGTAC
 luGlyPheTh rSerLeuAla SerGlnCysT hrAlaGlnGlu uLeuValMet

 ACCCTGAATG AGCTCTTTGC CCGGTTTGAC AAGCTGGCTG CGGAGAATCA 1400
 TGGGACTTAC TCGAGAAACG GGCCAAACTG TTCGACCGAC GCCTCTTAGT
 ThrLeuAsnG luLeuPheAl aArgPheAsp LysLeuAlaA laGluAsnHi

 CTGCCTGAGG ATCAAGATCT TGGGGGACTG TFACTACTGT GTGTCAGGGC 1450
 GACGGACTCC TAGTTCTAGA ACCCCCTGAC AATGATGACA CACAGTCCCG
 sCysLeuArg IleLysIleL euGlyAspCy sTyrTyrCys ValSerGlyL

 TGCCGGAGGC CCGGGCCGAC CATGCCCACT GCTGIGTGGA GATGGGGGTA 1500
 ACGGCTCCG GGCCCGGCTG GTACGGGIGA CGACACACCT CTACCCCAT
 euProGluAl aArgAlaAsp HisAlaHisC ysCysValGlu uMetGlyVal

 GACATGATTG AGGCCATCTC GCTGGTACGT GAGGTGACAG GTGTGAATGT 1550
 CTGTACTAAC TCCGGTAGAG CGACCATGCA CTCCACTGTC CACTTACA
 AspMetIleG luAlaIleSe rLeuValArg GluValThrG lyValAsnVa

 GAACATGCCG GTGGGCATCC ACAGCGGGCG CGTGCACTGC GCGTCTCTG 1600
 CTGTGACCG CACCCGTAGG TGTCGCCCCG GCACGTGACG CCGCAGGAAC
 lAsnMetArg ValGlyIleH isSerGlyAr gValHisCys GlyValLeuG

 GCITGCGGAA ATGGCAGTTC GATGIGTGGT CCAATGATGT GACCCTGGCC 1650
 CGAACGCCTT TACCGTCAAG CTACACACCA GGTTACTACA CTGGGACCGG
 lyLeuArgLy sTrpGlnPhe AspValTrpS erAsnAspVa lThrLeuAla

 AACCACATGG AGGCAGGAGG CCGGGCTGGC CGCATCCACA TCACTCGGGC 1700
 TTGGTGTACC TCCGTCTTCC GGCCCGACCG GCGTAGGTGT AGTGAGCCCG
 AsnHisMetG luAlaGlyGly yArgAlaGly ArgIleHisI leThrArgAl

 AACACTGCAG TACCTGAACG GGGACTACGA GGTGGAGCCA GGCCGIGGTG 1750
 TTGTGACGTC ATGGACTTGC CCTGATGCT CCACCTCGGT CCGGCACCAC
 aThrLeuGln TyrLeuAsnG lyAspTyrGlu uValGluPro GlyArgGlyG

 GCGAGCGCAA CCGGTACCTC AAGGAGCAGC ACATTGAGAC TTTCCTCATC 1800
 CGCTCGCGTT CGCATGGAG TTCCTCGTGG TGTAACCTCTG AAAGGAGTAG
 lyGluArgAs nAlaTyrLeu LysGluGlnH isIleGluTh rPheLeuIle

FIG. 1D

4/9

CTGGGCGCCA GCCAGAAACG GAAAGAGGAG AAGGCCATGC TGGCCAAGCT 1850
 GACCCGCGGT CGGTCTTTGC CTTTCTCCTC TTCCGGTACG ACCGGTTCGA
 LeuGlyAlaS erGlnLysAr gLysGluGlu LysAlaMetL euAlaLysLe

GCAGCGGACT CGGGCCAACT CCATGGAAAG GCTGATGCCG CGCTGGGTTC 1900
 CGTCGCCCTGA GCCCGGTGA GGTACCTTCC CGACTACGGC GCGACCCAAG
 uGlnArgThr ArgAlaAsnS erMetGluGl yLeuMetPro ArgTrpValP

CTGATCGTGC CTTCTCCCGG ACCAAGGACT CCAAGGCCTT CCGCCAGATG 1950
 GACTAGCACG GAAGAGGGCC TGGTTCCTGA GGTTCGGAA GCGGTCTAC
 roAspArgAl aPheSerArg ThrLysAspS erLysAlaPh eArgGlnMet

GGCATTGATG ATTCCAGCAA AGACAACCGG GGCACCCAAG ATGCCCTGAA 2000
 CCGTAACTAC TAAGGTGTT TCTGTGGCC CCGTGGGTTC TACGGGACTT
 GlyIleAspA spSerSerLy sAspAsnArg GlyThrGlnA spAlaLeuAs

CCCTGAGGAT GAGGTGGATG AGTTCCTGAG CCGTGCCATC GATGCCCGCA 2050
 GGGACTCCTA CTCCACCTAC TCAAGGACTC GGCACGGTAG CTACGGGCGT
 nProGluAsp GluValAspG luPheLeuSe rArgAlaIle AspAlaArgS

GCAITGATCA GCTGCGGAAG GACCATGTGC GCCGGTTTCT GCTCACCTTC 2100
 CGTAACTAGT CGACGCCCTTC CTGGTACACG CGGCCAAAGA CGAGTGGGAG
 erIleAspGl nLeuArgLys AspHisValA rgArgPheLe uLeuThrPhe

CAGAGAGAGG ATCTTGAGAA GAAGTACTCC CGGAAGGTGG ATCCCCGCTT 2150
 GTCTCTCTCC TAGAACTCTT CTTCATGAGG GCCTTCCACC TAGGGGCGAA
 GlnArgGluA spLeuGluLy sLysTyrSer ArgLysValA spProArgPh

CGGAGCCTAC GTTGCCCTGTG CCCTGTTGGT CTTCTGCTTC ATCTGCTTCA 2200
 GCCTCGGATG CAACCGACAC GGGACAACCA GAAGACGAAG TAGACGAAGT
 eGlyAlaTyr ValAlaCysA laLeuLeuVa lPheCysPhe IleCysPheI

TCCAGCTTCT CATCTTCCCA CACTCCACCC TGATGCTTGG GATCTATGCC 2250
 AGGTGGAAGA GTAGAAGGGT GTGAGGTGGG ACTACGAACC CTAGATACGG
 leGlnLeuLe uIlePhePro HisSerThrL euMetLeuGl yIleTyrAla

AGCATCTTCC TGCTGCTGCT AATCACCGTG CTGATCTGTG CTGTGTACTC 2300
 TCGTAGAAGG ACGACGACGA TTAGTGGCAC GACTAGACAC GACACATGAG
 SerIlePheL euLeuLeuLe uIleThrVal LeuIleCysA laValTyrSe

CTGTGGTTCT CTGTTCCCTA AGGCCCTGCA ACGTCTGTCC CGCAGCAITG 2350
 GACACCAAGA GACAAGGGAT TCCGGGACGT TGCAGACAGG GCGTCGTAAC
 rCysGlySer LeuPheProL ysAlaLeuGl nArgLeuSer ArgSerIleV

TCCGCTCACG GGCACATAGC ACCGCAGTTG GCATCTTTTC CGTCCTGCTT 2400
 AGGCGAGTGC CCGTGTATCG TGGCGTCAAC CGTAGAAAAG GCAGGACGAA
 alArgSerAr gAlaHisSer ThrAlaValG lyIlePheSe rValLeuLeu

FIG. 1E

5/9

GIGTTTACTT CTGCCATTGC CAACATGTTT ACCTGTAAAC ACACCCCCAT 2450
 CACAAATGAA GACGGTAAAC GTTGTACAAG TGGACATTGG TGTTGGGGGTA
 ValPheThrS erAlaIleAl aAsnMetPhe ThrCysAsnH isThrProIl

 ACGGAGCTGT GCAGCCCCGA TGCTGAATTT AACACCTGCT GACATCACTG 2500
 TGCTTGACA CGTCGGGCCT ACGACTTAAA TTGTGGACGA CTGTAGTGAC
 eArgSerCys AlaAlaArgM etLeuAsnLe uThrProAla AspIleThrA

 CCTGCCACCT GCAGCAGCTC AATTACTCTC TGGGCCTGGA TGCTCCCCCTG 2550
 GGACGGTGGG CGTCGTGAG TTAATGAGAG ACCCGGACCT ACGAGGGGAC
 laCysHisLe uGlnGlnLeu AsnTyrSerL euGlyLeuAs pAlaProLeu

 TGTTAGGGCA CCATGCCAC CTGCAGCTTT CCTGAGTACT TCATCGGGAA 2600
 ACACTCCCGT GGTACGGGTG GACGTGAAA GGACTCATGA AGTAGCCCTT
 CysGluGlyT hrMetProTh rCysSerPhe ProGluTyrP heIleGlyAs

 CATGCTGCTG AGTCTCTTGG CCAGCTCTGT CTTCCTGCAC ATCAGCAGCA 2650
 GTACGACGAC TCAGAGAACC GGTCGAGACA GAAGGACGTG TAGTCGTCTG
 nMetLeuLeu SerLeuLeuA laSerSerVa lPheLeuHis IleSerSerI

 TCGGGAAGTT GGCCATGATC TTTGTCTTGG GGCTCATCTA TTTGGTCTG 2700
 AGCCCTTCAA CCGTACTAG AAACAGAACC CCGAGTAGAT AAACCACGAC
 leGlyLysLe uAlaMetIle PheValLeuG lyLeuIleTy rLeuValLeu

 CTTCGTCTGG GTCCCCCAGC CACCATCTTT GACAACTATG ACCTACTGCT 2750
 GAAGACGACC CAGGGGGTCG GTGGTAGAAA CTGTTGATAC TGGATGACGA
 LeuLeuLeuG lyProProAl aThrIlePhe AspAsnTyrA spLeuLeuLe

 TGGCGTCCAT GGCTTGGCTT CTTCGAATGA GACCTTTGAT GGGCTGGACT 2800
 ACCGCAGGTA CCGAACCGAA GAAGGTTACT CTGGAAACTA CCGACCTGA
 uGlyValHis GlyLeuAlaS erSerAsnGl uThrPheAsp GlyLeuAspC

 GTCCAGCTGC AGGGAGGGTG GGCCTCAAAT ATATGACCCC TGTGATTCTG 2850
 CAGGTGACG TCCCTCCAC CGGGAGTTTA TATACTGGGG AACTAAGAC
 ysProAlaAl aGlyArgVal AlaLeuLysT yrMetThrPr oValIleLeu

 CTGGTGTFTG CGCTGGCGCT GTATCTGCAT GCTCAGCAGG TGGAGTCGAC 2900
 GACCACAAAC GCGACCGCA CATAGACGTA CGAGTCGTCC ACCTCAGCTG
 LeuValPheA laLeuAlaLe uTyrLeuHis AlaGlnGlnV alGluSerTh

 TGCCCGCCTA GACTTCCTCT GGAAACTACA GGCAACAGGG GAGAAGGAGG 2950
 ACCGGCGGAT CTGAAGGAGA CCTTTGATGT CCGTTGTCCC CTCTTCCTCC
 rAlaArgLeu AspPheLeuT rpLysLeuGl nAlaThrGly GluLysGluG

 AGATGGAGGA GCTACAGGCA TACAACCGGA GGCTGCTGCA TAACATTCTG 3000
 TCTACCTCCT CGATGTCCGT ATGTTGGCCT CCGACGACGT ATTGTAAAGAC
 luMetGluGl uLeuGlnAla TyrAsnArgA rgLeuLeuHi sAsnIleLeu

FIG. 1F

6/9

CCCAAGGACG TGGGGGCCCC CTTCCTGGCC CGGGAGCGCC GCAATGATGA 3050
 GGGTTCCTGC ACCGCCGGGT GAAGGACCGG GCCCTCGCGG CGTTACTACT
 ProLysAspV alAlaAlaHi sPheLeuAla ArgGluArgA rgAsnAspGl

 ACTCTACTAT CAGTCGTGTG AGTGTGTGGC TGTATGTGTT GCCTCCATTG 3100
 TGAGATGATA GTCAGCACAC TCACACACCG ACAATACAAA CGGAGGTAAAC
 uLeuTyrTyr GlnSerCysG luCysValAl aValMetPhe AlaSerIleA

 CCAACTTCTC TGAGTTCTAT GTGGAGCTGG AGGCAAACAA TGAGGGTGTG 3150
 GGTGAAGAG ACTCAAGATA CACCTCGACC TCCGTTTGTT ACTCCACAG
 laAsnPheSe rGluPheTyr ValGluLeuG luAlaAsnAs nGluGlyVal

 GAGTGCCTGC GGCTGCTCAA CGAGATCATC GCTGACTTTG ATGAGATTAT 3200
 CTCACGGACG CCGACGAGTT GCTCTAGTAG CGACTGAAAC TACTCTAATA
 GluCysLeuA rgLeuLeuAs nGluIleIle AlaAspPheA spGluIleIl

 CAGCGAGGAG CGGTTCGGC AGCTGGAAAA GATCAAGACG ATTGGTAGCA 3250
 GTCGCTCCTC GCCAAGGCCG TCGACCTTTT CTAGTTCTGC TAACCATCGT
 eSerGluGlu ArgPheArgG lnLeuGluLy sIleLysThr IleGlySerT

 CCTACATGGC TGCTCAGGG CTGAACGCCA GCACCTACGA TCAGGTGGGC 3300
 GGATGTACCG ACGGAGTCCC GACTTGGCGT CGTGGATGCT AGTCCACCCG
 nrTyrMetAl aAlaSerGly LeuAsnAlaS erThrTyrAs pGlnValGly

 CGCTCCCACA TCACTGCCCT GGCTGACTAC GCCATGCGGC TCATGGAGCA 3350
 GCGAGGGTGT AGTGACGGGA CCGACTGATG CCGTACGCCG AGTACCTCGT
 ArgSerHisI leThrAlaLe uAlaAspTyr AlaMetArgL euMetGluGl

 GATGAAGCAC ATCAATGAGC ACTCCTTCAA CAATTTCAG ATGAAGATTG 3400
 CTACTTCGTG TAGTTACTCG TGAGGAAGTT GTTAAAGGTC TACTTCTAAC
 nMetLysHis IleAsnGluH isSerPheAs nAsnPheGln MetLysIleG

 GGCTGAACAT GGGCCCAGTC GTGGCAGGTG TCATCGGGGC TCGGAAGCCA 3450
 CCGACTTGTA CCCGGGTCAG CACCGTCCAC AGTAGCCCCG AGCCTTCGGT
 lyLeuAsnMe tGlyProVal ValAlaGlyV alIleGlyAl aArgLysPro

 CAGTATGACA TCTGGGGGAA CACAGTGAAT GTCTCTAGTC GTATGGACAG 3500
 GTCATACGT AGACCCCTT GTGTCACTTA CAGAGATCAG CATACCTGTC
 GlnTyrAspI leTrpGlyAs nThrValAsn ValSerSerA rgMetAspSe

 CACGGGGGTC CCCGACCGAA TCCAGGTGAC CACGGACCTG TACCAGGTTC 3550
 GTGCCCCCAG GGGCTGGCTT AGGTCCACTG GTGCCGAC ATGGTCCAAG
 rThrGlyVal ProAspArgI leGlnValTh rThrAspLeu TyrGlnValL

 TAGCTGCCAA GGGCTACCAG CTGGAGTGTC GAGGGGTGGT CAAGGTGAAG 3600
 ATGACGGT CCAGATGGTC GACCTCACAG CTCCCCACCA GTTCCACTTC
 euAlaAlaLy sGlyTyrGln LeuGluCysA rgGlyValVa lLysValLys

7/9

FIG. 16

GGCAAGGGGG AGATGACCAC CTACTTCCTC AATGGGGGCC CCAGCAGTTA 3650
 CCGTTCCCCC TCTACTGGTG GATGAAGGAG TTACCCCGG GGTCTCAAT
 GlyLysGlyG luMetThrTh rTyrPheLeu AsnGlyGlyP roSerSer

ACAGGGCCCA GCCACAAATT CAGCTGAAGG GACCAAGGTG GGCATTGAGT 3700
 TGTCOCGGGT CCGTGTTTAA GTGACTTCC CTGGTTCCAC CCGTAACTCA

GGACTCTGTG CTCACTGGGT GGAGCTGTGG CAGGGGGCAC TGAGCCTCCA 3750
 CCTGAGACAC GAGTGACCCA CCTCGACACC GTCCCCGTG ACTCGGAGGT

GACCCTGCTA ACCACAAAAG GGAACATCCC AGCAGGCTGT GCTTGGATCA 3800
 CTGGGACGAT TGGTGTTTTC CCTTGTAGGG TCGTCCGACA CGAACCTAGT

TGCTCGTCTG CCCTCAAGCT GGAAAACAAG GGGCTACCTA CCGAGAGGAT 3850
 ACGAGCAGAC GGGAGTTGGA CCTTTTGTTC CCGATGGAT GGCTCTCCTA

TATGCAAGTG ACTTCTTTTC TTAATTGGGG TAGGGCTGTT CCTCTCCAA 3900
 ATACGTTTAC TGAAAGAAAG AATGAACCCC ATCCCGACAA GGGAGAGGTT

TCTTCCAGCC TTTGGGAGCA GGGGAGGGGT CAGTAGCAGA AGCAGAGGGA 3950
 AGAAGGTCCG AAACCTCGT CCCCTCCCCA GTCATCGTCT TCGTCTCCT

GGCCTCTTGC CTGAGGGATT AAAATGGCAG CTGCGCATGC CTACCCCTCC 4000
 CCGGAGAACG GACTCCCTAA TTTTACCGTC GAACGGTACG GATGGGAAGG

CTGTCTGTCT GGGCAGCAGG TTCAGGGCTG AGCCCTTCTT TTCCCTCTTT 4050
 GACAGACAGA CCCGTCTGCC AAGTCCCGAC TCGGAAGAA AAGGGAGAAA

TTTCTTGGGA ATATTTTGTG CAATATTTTG TACAAAGACA GGCATGAGGA 4100
 AAAGGACCTT TATAAAACAT GTTATAAAAC ATGTTTCTGT CCGTACTCCT

GTGCCTATTC CATGCTTGCC TTTGCAATAC CTGCATCCCC AGCACTGGTC 4150
 CACGGATAAG GTACGAACGG AAACGTTATG GACGTAGGGG TCGTGACCAG

CTGGGCACCT CCCCACCCCA GCCAGGTGTC CCTCCTATGC ACAGAGCAGA 4200
 GACCCGTGAA GGGGTGGGGT CCGTCCACAG GGAGGATACG TGTCTCGTCT

SUBSTITUTE SHEET (RULE 26)

8/9

FIG. 1H

GGAGGGAGAA GCTCTGGGGA GCCAGCTTTG GCCATATTTT AGGAGAATGT 4250
CCTCCCTCTT CGAGACCCCT CGGTCGAAAC CGGTATAAAG TCCTCTTACA

TTCCATGTGC CAAATCTTAG TCCCATGATC TGTCGCCAAA GGGGAACAAA 4300
AAGGTACACG GTTTAGAATC AGGGTACTAG ACAGGGGTTC CCCCTTGTTT

GGGACCTCTG ACAGCTTAGA TTTAGCCCCA GTTCCTGCAC GCTCCAGGGA 4350
CCCTGGAGAC TGTCGAATCT AAATCGGGGT CAAGGACGTG CGAGGTCCCT

ACGGGGTGTC TGCCCTCACT GGTACTGTGA AAAATGCTCA GAGAGCAAGC 4400
TGCCCCACAG ACCGGAGTGA CCATGACACT TTTTACGAGT CTCTCGTTTC

CTGTGTGTGG GGATGTCAGG TCAGGAGCTG GAAGTTCACC TGCAGGTGCC 4450
GACACACACC CCTACAGTCC AGTCCTCGAC CTTCAGTGG ACGTCCACGG

AAAGAGCAGG CCGGCCAGGG CTGGGGCAGT GCCAGACTCT GATCTGAGGA 4500
TTTCTCGTCC GGCCGGTCCC GACCCCGTCA CGGTCTGAGA CTAGACTCCT

CCCCGTCCGG GTCCAGATCA GGTCACCTCT CCCCAGTGCT CTCTTGCTGT 4550
GGGGCAGCCC CAGGTCTAGT CCAGTGAGAC GGGGTACGA GAGAACGACA

CTGCTGACAA GGGGGCATGG AGCATCTCTT CCTCTTCTGT TGCCAAATAG 4600
GACGACTGTT CCCCCGTACC TCGTAGAGAA GGAGAAGACA ACGGTTTATC

AAAAGGGTCA GGGCATGGAG AAAGGTGACC CTGATCCCAA ACCTGCCCTC 4650
TTTTCCAGT CCGTACCTC TTTCCTACTG GACTAGGGTT TGGACGGGAG

CCAAGTCTCT GTGTGTGGGG AGGGCCCGTG TGTTTGTTGA ACTGTGTGTG 4700
GGTTCAGAGA CCACAACCC TCCCGGGCAC ACAAACACAT TGACACACAC

CATGTTGGTC TTTGTGTGCA TATCTGTTTT CCAGGTCTAT GTGAGTCCTT 4750
GTACAACCAG AAACACACGT ATAGACAAAA GGTCAGATA CACTCAGGAA

GTGCTCCTGC TCCTCAGCTC TCCACCCAG GTTGCCCTCT TCCTGTGGGC 4800
CAGGAGGACG AGGAGTCGAG AGGTGGGGTC CAACGGAGAG AGGACACCCG

FIG. 11

CTCTGTCCTC TGGGAATAAA GCAGGGTTC CTACTTCAGG GGATGTAGAG 4850
GAGACAGAAG ACCCTTATTT CGTCCCAAAG GATGAAGTCC CCTACATCTC

AGATGCCCAG GTTGACACAGG AGTGGGATGG GGTGTGGTAG CAAAAGGAGG 4900
TCTACGGGTC CAACGTGTCC TCACCTACC CCACACCATC GTTTTCCTCC

GAGAGGAGTC CTTTTGTGTC CAAATCCCTA AGTGCCGTTC GG 4942
CTCTCCTCAG GAAAAACAG GTTTAGGGAT TCACGGCAAG CC

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/13694

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N9/88 C12N15/60 C12N15/85 C12N5/10

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HELLEVUO K ET AL: "A novel adenylyl cyclase sequence cloned from the human erythroleukemia cell line." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1993 APR 15) 192 (1) 311-8. JOURNAL CODE: 9Y8. ISSN: 0006-291X., XP002084072 * see esp. p.316 last par.; figure 1 *	1-7
A	HABER N. ET AL.: "Chromosomal mapping of human adenylyl cyclase genes type III, type V and type VI" HUM. GENET. (1994), 94(1), 69-73 , XP002084073 see the whole document -/--	1-7

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 November 1998

Date of mailing of the international search report

27/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kania, T

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/13694

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>YOSHIMURA M. AND COOPER D.: "Cloning and expression of a Ca²⁺-inhibitable adenylyl cyclase from NCB-20 cells"</p> <p>PNAS, U.S.A.,</p> <p>vol. 89, no. 15, 1 August 1992, pages 6716-6720, XP002084074</p> <p>cited in the application</p> <p>see the whole document</p>	1-7
A	<p>KATSUSHIKA S. ET AL.: "Cloning and characterization of a sixth adenylyl cyclase isoform: types V and VI constitute a subgroup within the mammalian adenylyl cyclase family"</p> <p>PNAS, U.S.A.,</p> <p>vol. 89, no. 18, 15 September 1992, pages 8774-8778, XP002056510</p> <p>cited in the application</p> <p>see the whole document</p>	1-7
A	<p>EP 0 543 137 A (AMERICAN CYANAMID CO)</p> <p>26 May 1993</p> <p>cited in the application</p> <p>see the whole document</p>	1-7
P,X	<p>WO 98 10085 A (COLLATERAL THERAPEUTICS; PING PEIPEI (US); POST STEVEN R (US); GAO) 12 March 1998</p> <p>* see esp. example 5.3, figure 12a *</p>	1-7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/13694

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0543137 A	26-05-1993	US 5334521 A	02-08-1994
		AU 666146 B	01-02-1996
		AU 2844992 A	20-05-1993
		CA 2082986 A	19-05-1993
		JP 5276961 A	26-10-1993
		NZ 245068 A	26-05-1995
		US 5578481 A	26-11-1996
		ZA 9208877 A	12-05-1993
WO 9810085 A	12-03-1998	AU 4251997 A	26-03-1998